2 Key Players In The GLP-1 Market Novo Nordisk Positioning: Novo Nordisk (Novo) is the undisputed leader in the GLP-1 receptor agonist market, largely due to the success of semaglutide, which is marketed as Ozempic for diabetes and Wegovy for weight management
Subcutaneous injections of semaglutide were administered with increasing dosages on a weekly basis in the second month and were continued after the removal of the intragastric balloon
Patients with hypothyroidism typically fall at the moderate end of this range, partly because baseline metabolism is lower
Areas of Treatment Semaglutide Known as a breakthrough weight loss medication, Semaglutide helps individuals shed excess pounds by targeting fat throughout the body
Key Takeaway: Safety is a partnership between the medication, your provider, and your lifestyle choices
- Red flag: the site will not disclose exact concentration, solvent, and additives when you ask